Ardelyx is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of gastrointestinal and cardiorenal diseases. The company's pipeline includes several product candidates targeting conditions such ashyperkalemia, constipation-predominant irritable bowel syndrome (IBS-C), and others. Ardelyx's lead product candidate, ten apanor, is an orally-administered small molecule inhibitor of sodium-hydrogen exchanger 3 (NHE3), currently in clinical development for various indications including the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis and IBS-C. The company's goal is to address unmet medical needs and improve the lives of patients through its innovative therapeutic approaches ingastrointestinal and cardiorenal diseases.